《大行報告》瑞信降昊海生物科技(06826.HK)目標價至60元 評級「跑贏大市」
瑞信發表報告指,昊海生物科技(06826.HK)有良好定位,可受惠於美容及眼科材料行業的趨勢,預料集團的透明質酸(HA)真皮填充劑及OK鏡片將成為今年的主要增長動力,估計收入分別按年增長50%和65%。
該行預期,昊海與A股同業的估值折讓,及集團A股及H股的折讓將於今年收窄,主因有更多同業尋求在香港雙重上市。
瑞信維持昊海生物科技H股「跑贏大市」評級,目標價由70元降至60元,以反映刪除早前的市盈率向上調整因素。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.